MNPR-202 (camsirubicin)
Advanced soft tissue sarcoma
Phase 1bLicensed to NorthStar Medical Radioisotopes (2024)
Key Facts
Indication
Advanced soft tissue sarcoma
Phase
Phase 1b
Status
Licensed to NorthStar Medical Radioisotopes (2024)
Company
About Monopar Therapeutics
Monopar Therapeutics is a publicly traded biotech company (NASDAQ: MNPR) advancing a pipeline of novel oncology candidates. Its most advanced asset, Validive (clonidine HCl mucoadhesive buccal tablet), is designed to prevent a debilitating side effect of cancer treatment and has received Fast Track and Orphan Drug designations from the FDA. The company's strategy centers on developing targeted therapies for underserved oncology indications with high unmet medical need.
View full company profile